Clinical trials located in

Harefield

Harefield city is located in United Kingdom. Currently, 7 clinical trials are being conducted in this city.

Harefield, nestled in the London Borough of Hillingdon, UK, boasts a rich history dating back to the Domesday Book of 1086. This village is distinguished by its unique position as the most westerly settlement in London. Harefield is home to the renowned Harefield Hospital, a leading heart and lung transplant center. The village’s St. Mary’s Church, with parts dating from the 12th century, houses the graves of Australian soldiers from WWI, reflecting its deep historical ties. Surrounded by green belt land, Harefield offers a blend of historical charm and natural beauty.

  • CT-EU-00057161

    Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Assessing olpasiran treatment for heart disease and elevated cholesterol

    Tests named ‘OCEAN(a)’ are being conducted, focusing on a medication called ‘olpasiran’. Put simply, the potential of this medication in preventing serious heart episodes in individuals with Atherosclerotic Cardiovascular Disease and an elevated level of a fat protein, Lipoprotein(a), is under examination. The effect of a harmless, dummy pill (placebo) is compared to that of the actual medication, olpasiran, in individuals with these conditions. The primary goal is to determine whether olpasiran can reduce the risk of death due to heart disease, occurrence of heart attacks, or the necessity for sudden surgery to clear blocked heart vessels.

    • Olpasiran
  • Investigating opelconazole treatment for refractory invasive pulmonary aspergillosis

    This study focuses on Refractory Invasive Pulmonary Aspergillosis (IPA), a serious lung infection caused by a type of fungus that does not respond to standard antifungal treatments. The therapy being tested involves a drug called PC945 (Opelconazole). PC945 will be administered through a nebulizer, which turns the liquid medicine into a mist to be inhaled directly into the lungs.

    The study aims to evaluate the safety and effectiveness of PC945 when used along with other antifungal medications in treating patients whose IPA is resistant to regular treatment.

    Participants in the study will be randomly assigned to one of two groups. One group will receive PC945 via a nebulizer two times a day, while the other group will receive a placebo that looks like the medication but does not have any active ingredients. The study is designed in such a way that neither the participants nor the researchers will know who is receiving PC945 and who is receiving the placebo.

    The main purpose of the study is to see how well PC945 works in combination with standard antifungal treatments by comparing overall health improvements in participants. The study also closely monitors the safety of using PC945 over a specific period.

    • Opelconazole/PC945
  • Assessing the efficacy of atuliflapon in uncontrolled asthma relief

    This study is looking at atuliflapon, a new medication, for adults with moderate to severe uncontrolled asthma. The trial is a Phase 2 study, which means it’s testing how effective and safe atuliflapon is. About 1,102 adults who are already using asthma medications will be part of this study. They will take atuliflapon or a placebo once a day for 12 weeks. The goal is to see if atuliflapon can help reduce asthma attacks and improve breathing in people whose asthma isn’t well-controlled with their current treatments.

    • Atuliflapon
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    • Inotuzumab Ozogamicin
    • 6-tioguanine
    • Blinatumomab
    • Imatinib
    • Dexamethasone
    • Vincristine
    • Doxorubicin
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    • Sacituzumab govitecan
    • Carboplatin
    • Cisplatin
    • Capecitabine

See more clinical trials in other cities in United Kingdom:

.